Can-Fite BioPharma (NYSE:CANF) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a report published on Saturday. The brokerage issued a sell rating on the stock.

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Can-Fite BioPharma in a report on Monday, March 3rd.

Can-Fite BioPharma Trading Up 1.2 %

Shares of NYSE:CANF opened at $1.65 on Friday. Can-Fite BioPharma has a 52 week low of $1.29 and a 52 week high of $4.69. The company’s 50 day moving average is $1.58 and its two-hundred day moving average is $1.88. The company has a market cap of $5.84 million, a PE ratio of -0.92 and a beta of 1.12.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers grew its holdings in Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 26,880 shares of the company’s stock after buying an additional 9,935 shares during the period. Rhumbline Advisers owned 0.76% of Can-Fite BioPharma worth $44,000 at the end of the most recent reporting period. 21.00% of the stock is currently owned by hedge funds and other institutional investors.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.